Synvista Therapeutics Inc (SYNI)

[es1]

Well there are VERY FEW shares so if it does drop below a penny I think I might have to buy the entire company LOL

I dont expect any news. I have been looking into this company CEO and it does not look promising. I dont expect the typical pink moves but I dont expect anything else either. The CEO is not much of a doctor or CEO from the info I am finding. I would contact the SEC and check into it further but I only expect a move here based on the low share count.

Executive Profile*
Noah Berkowitz M.D., Ph.D.
Chief Executive Officer, President, Secretary and Director, Synvista Therapeutics, Inc.
Age Total Calculated Compensation This person is connected to 10 board members in 1 different organizations across 1 different industries.

See Board Relationships
48 --

Background*
Noah Berkowitz, M.D., Ph.D. has been the President and Chief Executive Officer of Synvista Therapeutics, Inc. (formerly Alteon Inc.) since July 21, 2006 and also serves as its Secretary. Dr. Berkowitz served as Vice President of Business Development of idGENE Pharmaceuticals Ltd. Prior to joining Synvista Therapeutics Inc., he founded HaptoGuard, where he served as President and Chief Executive Officer. Prior to founding HaptoGuard, he served as Vice-President of Clinical ... Development at IMPATH Inc., where he developed a division, IMPATH Predictive Oncology, focused on biopharmaceutical partnerships supporting the discovery and development of cancer-related targeted diagnostics and therapeutics. Prior to IMPATH, Dr. Berkowitz founded Physician Choice. He has been a Director of Synvista Therapeutics Inc. since July 21, 2006. Dr. Berkowitz earned his B.A., M.D., and Ph.D. from Columbia University and trained at the National Cancer Institute in medical oncology.

All good till you read this...

IMPATH was a company with over 1200 employees and an annual income of over one quarter of a billion dollars. Immediately after completion of his residency, Dr. Berkowitz’s became Vice President of Information Services for IMPATH. He maintained his private residence in Silver Spring, Maryland, not far from the National Cancer Institute in Bethesda. We speculated in our document that his actual role was to serve as a ‘listening post’ for research data at the NCI that could be used by IMPATH to grow their business. One of the major components of the company was the "IMPATH Predictive Oncology" division (IPO) which was made possible, according to their press release, by the acquisition of Dr. Berkowitz’s ‘Physician Choice, Inc.’
The reader of this document should read reporter David Willman’s recent expose (12/22/04) of the unethical behavior of multiple researchers at the National Institutes of Health (see http://www.latimes.com). Dr. Berkowitz appears to have been using Government data gathered at the NCI for personal profit. According to the LA Times, this seems to have been commonplace. (see the end of this document for instructions on How to View the Exhibits)
On October 22, 2001, IMPATH announced it was reimbursing the Government $9 million dollars to settle an investigation over their Medicare billing practices. IMPATH declared bankruptcy in the summer of 2003 after an SEC audit alleged they had systematically misrepresented their accounts receivable to their investors. Dr. Berkowitz left the company after the initial Medicare investigation was commenced.

This entire set of charges are pretty bad if true. I dont know if anything ever came of this.

http://www.med-malpractice.com/berk1.htm

It could be nothing more then a kid died and they blame the doctor